• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

OrganoClick: Positive sales in binders, weak elsewhere - ABG

OrganoClick

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Q4 sales SEK 18m (-14% y-o-y), -16% vs. ABGSCe
* EBIT adj. of SEK -11m (vs. ABGSCe -5.5m)
* NW&FT showing signs of improvement, weaker GC&MP and FW


Q4 results

Sales came in at SEK 18m (-16% vs. ABGSCe 22m), -14% y-o-y (-14% org.). NW&FT increased sales y-o-y, while GC&MP and FW had a challenging quarter. Management writes that the positive effect in NW&FT was partly due to a volume shift from Q3 but also slightly improving end-markets. EBIT adj. was SEK -11m (vs. ABGSCe -5.5m). EBIT was adjusted for restructuring costs and write-downs of inventory totalling SEK 7.7m. FCF lease adj. came in at SEK -1.8m (vs. ABGSCe -4.1m). During the quarter, a savings programme of SEK 20m was implemented which management writes will have almost full effect from Jan '26.


Estimates and outlook

On numbers alone, '25e-'27e sales change by -3%, and EBIT adj. changes by SEK 5m. On outlook, management writes that it aims to deliver significantly improved 2026 earnings, supported by a lower cost base and improving volumes.


Valuation

The share has returned -3% L3M (vs. peer median +2% and OMX Stockholm Allshare +5%), and is currently trading at 2.2x-2.0x '26e-'27e EV/Sales on our pre-report estimates vs. the peer median of 2.2x-1.4x.